<code id='90061AE1AC'></code><style id='90061AE1AC'></style>
    • <acronym id='90061AE1AC'></acronym>
      <center id='90061AE1AC'><center id='90061AE1AC'><tfoot id='90061AE1AC'></tfoot></center><abbr id='90061AE1AC'><dir id='90061AE1AC'><tfoot id='90061AE1AC'></tfoot><noframes id='90061AE1AC'>

    • <optgroup id='90061AE1AC'><strike id='90061AE1AC'><sup id='90061AE1AC'></sup></strike><code id='90061AE1AC'></code></optgroup>
        1. <b id='90061AE1AC'><label id='90061AE1AC'><select id='90061AE1AC'><dt id='90061AE1AC'><span id='90061AE1AC'></span></dt></select></label></b><u id='90061AE1AC'></u>
          <i id='90061AE1AC'><strike id='90061AE1AC'><tt id='90061AE1AC'><pre id='90061AE1AC'></pre></tt></strike></i>

          Home / Wikipedia / Wikipedia

          Wikipedia


          Wikipedia

          author:knowledge    Page View:9338
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In